Ursodeoxycholic acid to inhibit the growth of hepatic metastases

被引:7
作者
Keith, BD [1 ]
机构
[1] NCI, Med Branch, Natl Naval Med Ctr, Bethesda, MD 20889 USA
关键词
D O I
10.1054/mehy.2000.1071
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 [基础医学];
摘要
Cancer can be resistant to apoptosis. If such cancers had apoptotic stimuli in their microenvironment, these stimuli might induce apoptosis in surrounding host cells. The majority of host cells at the peritumoral margins of liver metastases are undergoing apoptosis. Damage to the bile duct system may result in bile acid release, which may cause apoptosis in surrounding host cells. Metastatic cells may be releasing substances, such as transforming growth factor-beta 1 (TGF-beta 1), that cause apoptosis in surrounding host tissue. Ursodeoxycholic acid might inhibit the growth of hepatic metastases that are resistant to apoptotic stimuli such as bile acids and TGF-beta 1. Ursodeoxycholic acid decreases apoptosis caused by other bile acids and TGF-beta 1. Chemotherapy of hepatic metastases resistant to apoptosis might cause apoptosis more in peritumoral host cells than in cancer cells. Antiapoptotic therapy might be effective in cancer sensitive to apoptosis depending on its interactions with chemotherapy and tumor cells. (C) 2000 Harcourt Publishers Ltd.
引用
收藏
页码:379 / 382
页数:4
相关论文
共 36 条
[1]
URSODEOXYCHOLIC ACID IN THE TREATMENT OF CHOLESTEROL CHOLELITHIASIS .1. [J].
BACHRACH, WH ;
HOFMANN, AF .
DIGESTIVE DISEASES AND SCIENCES, 1982, 27 (08) :737-761
[2]
Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes [J].
Benz, C ;
Angermüller, S ;
Töx, U ;
Klöters-Plachky, P ;
Riedel, HD ;
Sauer, P ;
Stremmel, W ;
Stiehl, A .
JOURNAL OF HEPATOLOGY, 1998, 28 (01) :99-106
[3]
The role of cell death and cell proliferation in the promotion of rat liver tumours by tamoxifen [J].
Carthew, P ;
Nolan, BM ;
Edwards, RE ;
Smith, LL .
CANCER LETTERS, 1996, 106 (02) :163-169
[4]
Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas [J].
Faubion, WA ;
Guicciardi, ME ;
Miyoshi, H ;
Bronk, SF ;
Roberts, PJ ;
Svingen, PA ;
Kaufmann, SH ;
Gores, GJ .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (01) :137-145
[5]
FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549
[6]
ENHANCED EXPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA ISOFORMS IN PANCREATIC-CANCER CORRELATES WITH DECREASED SURVIVAL [J].
FRIESS, H ;
YAMANAKA, Y ;
BUCHLER, M ;
EBERT, M ;
BEGER, HG ;
GOLD, LI ;
KORC, M .
GASTROENTEROLOGY, 1993, 105 (06) :1846-1856
[7]
INVOLVEMENT OF THE CD95 (APO-1/FAS) RECEPTOR AND LIGAND IN LIVER-DAMAGE [J].
GALLE, PR ;
HOFMANN, WJ ;
WALCZAK, H ;
SCHALLER, H ;
OTTO, G ;
STREMMEL, W ;
KRAMMER, PH ;
RUNKELL, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (05) :1223-1230
[8]
Garewal H, 1996, CANCER RES, V56, P1480
[9]
TGF-beta-mediated hepatocellular apoptosis by rat and human hepatoma cells and primary rat hepatocytes [J].
Gressner, AM ;
Lahme, B ;
Mannherz, HG ;
Polzar, B .
JOURNAL OF HEPATOLOGY, 1997, 26 (05) :1079-1092
[10]
Hartmann K, 1997, J IMMUNOL, V159, P4006